ABSTRACT
In early EU policy, agbiotech innovation was nearly removed from political debate. Decisions were left to ‘risk-based regulation’, a policy confl ating risk assessment, the available science and offi cial expert advice. In this scenario, EC expert committees would provide a scientifi c basis for the Commission to approve GM products, which could then freely circulate on the internal market.
